Histamine receptors as drug target: Current and future therapeutics.
Abstract
Histamine is a neurotransmitter responsible for central regulation of inflammatory reactions. Initial studies were done by Sir Henry Dale in 1993. Histamine acts on its four type of receptors. H1 and H2 are well-established with pharmacological status. H1 receptors are mainly linked with inflammatory responses and developed to mitigate the inflammatory symptoms. While H2 antagonists are established with their role in decreasing basal gastric secretions by decreasing the cyclic adenylyl mono phosphate (cAMP), thus used as therapy line for gastric ulcers. H3 being located centrally imparts its central effects in cognitive functions that are pain, sleep, and memory modulation of neurotransmitters release including, dopamine, acetylcholine, noradrenalin and serotonin. H4 is discovered recently during cloning of H3 and found on immune related cells as, mast cells, T cells and dendrites. Experimental studies are helping in development of more pharmacologically worth drugs that can increase the quality of life.
Downloads
References
Coruzzi G, Adami M, Guaita E, de Esch IJ and Leurs R. Anti-inflammatory and ant nociceptive effects of the selective histamine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced acute inflammation. Eur J Pharmacol 2007; 563(1-3):240-4. DOI: https://doi.org/10.1016/j.ejphar.2007.02.026
Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD and Brioni JD. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 2008; 154(6):1166-81. DOI: https://doi.org/10.1038/bjp.2008.147
Gemkow MJ, Davenport AJ, Harich S, Ellenbroek BA, Cesura A and Hallett D. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today 2009; 14(9-10):509-15. DOI: https://doi.org/10.1016/j.drudis.2009.02.011
Holgate ST, Canonica GW, Simons FE, Taglialatela M, Tharp M, Timmerman H. et al. This Consensus Group was convened under the auspices of the British Society for Allergy and Clinical Immunology. Consensus group on new‐generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003; 33(9):1305-24. DOI: https://doi.org/10.1046/j.1365-2222.2003.01769.x
Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN. et al. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology 1985; 88(4):1026-33. DOI: https://doi.org/10.1016/S0016 5085(85)80024-X
Jutel M, Akdis M. and Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 2009; 39(12):1786-800. DOI: https://doi.org/10.1111/j.1365-2222.2009.03374.x
Leurs R, Chazot PL, Shenton FC, Lim HD. and De Esch IJ. Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol 2009; 157(1):14-23. DOI: https://doi.org/10.1111/j.1476-5381.2009.00250.x
Lüllmann H, Mohr K, Hein L. and Bieger D. Color atlas of pharmacology. New York: Thieme; 2000.
Maintz L, “American journal of clinical nutrition,” pp. 12-28, 2008.
Mattila MJ, Paa. And kari I. Variations among non-sedating antihistamines: are there real differences?. Eur J Clin Pharmacol 1999; 55(2):85-93. DOI: https://doi.org/10.1007/s002280050600
Medhurst AD, Atkins AR, Beresford IJ, Bracken BK, Briggs MA, Calver AR. et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007; 321(3):1032-45. DOI: https://doi.org/10.1124/jpet.107.120311
Munzar P, Tanda G, Justinova Z. and Goldberg SR. Histamine h3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release. Neuropsychopharmacology 2004; 29(4):705. DOI: https://doi.org/10.1038/sj.npp.1300380
Howland RD, Mycek MJ, Harvey RA, Champe PC. Lippincott's illustrated reviews: Pharmacology. Philadelphia: Lippincott Williams & Wilkins; 2006.
Nakamura T, Itadani H, Hidaka Y, Ohta M. and Tanaka K. Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun 2000; 279(2):615-20. DOI: https://doi.org/10.1006/bbrc.2000.4008
Pfizer L, “Tetra hydro naph thyridine derivative,” WIPO, patentscope, Pub no. WO/2007/052124, May 2007.
Rang HP, Dale MM, Ritter JM, and Moore PK, “Pharmacology,” Oxford journals, pp. 229, 2003.
Rico S, Antonijoan RM. and Barbanoj MJ. Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines. Journal of asthma and allergy 2009; 2:73-92. DOI https://doi.org/10.2147/JAA.S3108
Roberts DJ. A preclinical overview of ebastine. Drugs 1996 Jul 1; 52(1):8-14.
Takahashi M. and Katayama Y. Reversal of the tolerance phenomenon by the intermittent administration of a histamine H2‐receptor antagonist. Can J Gastroenterol Hepatol 2010; 25(9):1493-7. DOI: https://doi.org/10.1111/j.1440-1746.2010.06308.x
Wagner E, Wittmann HJ, Elz S. and Strasser A. Mepyramine–JNJ7777120-hybrid compounds show high affinity to hH1R, but low affinity to hH4R. Bioorg Med Chem Lett 2011; 21(21):6274-80. DOI: https://doi.org/10.1016/j.bmcl.2011.09.001
Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardio toxic actions of terfenadine. JAMA 1993; 269(12):1532-6. DOI: https://doi.org/10.1001/jama.1993.03500120070028
Scadding G. Predicting and Establishing the Clinical Efficacy of a Histamine H 1-Receptor Antagonist. Clin Drug Investig 2005; 25(3):153-64. DOI: https://doi.org/10.2165/00044011-200525030-00001
Li M, Hu J, Chen Z, Meng J, Wang H, Ma X. et at. Evidence for histamine as a neurotransmitter in the cardiac sympathetic nervous system. Am J Physiol Lung Cell Mol Physiol 2006; 1. DOI: https://doi.org/10.1152/ajpheart.00939.2005
Copyright (c) 2019 Journal of Shifa Tameer-e-Millat University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Shifa Tameer-e-Millat University (JSTMU) is the owner of all copyright to any work published in the journal. Any material printed in JSTMU may not be reproduced without the permission of the editors or publisher. The Journal accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing and/or decision in this journal. The Editorial Board makes every effort to ensure the accuracy and authenticity of material printed in the journal. However, conclusions and statements expressed are views of the authors and do not necessarily reflect the opinions of the Editorial Board or JSTMU.
Content of this journal is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
